Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 1998American Journal of Clinical Oncology

Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With Sarcomas

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does dose-intensive doxorubicin and ifosfamide combination chemotherapy improve response rates in patients with high-risk or metastatic sarcomas?

Population

33 evaluable patients with either metastatic sarcoma or primary sarcomas with a high-risk for metastases…

Design

Cohort

Authors

SPShreyaskumar PatelSVSaroj Vadhan‐RajMBM. A. Burgess

Discussion

Loading...

Member takes

Overview

May support consideration in selected sarcomas despite toxicity risks; leaves open randomized confirmation of benefit over standard regimens.

Structured PICO

Does dose-intensive doxorubicin and ifosfamide combination chemotherapy improve response rates in patients with high-risk or metastatic sarcomas?

P
Population
33 evaluable patients with either metastatic sarcoma or primary sarcomas with a high-risk for metastases (all except one previously untreated with chemotherapy), median age 45 years.
I
Intervention
Dose-intensive doxorubicin and ifosfamide combination chemotherapy. Protocol 1: doxorubicin 75 mg/m2 (72-hour infusion days 1-3) and ifosfamide 2 g/m2/d (over 2 hours x 5, days 1-5). Protocol 2: doxorubicin 90 mg/m2 (72-hour continuous infusion) and ifosfamide 2.5 g/m2/d for 4 days with prophylactic G-CSF. Median of 4 cycles administered.
O
Outcome
Response rate (pathologic complete response and partial response)surrogate

Dose-intensive doxorubicin plus ifosfamide is a highly active and feasible regimen in appropriately selected patients with sarcomas, though it carries risks of significant neutropenia and potential cardiotoxicity.

Cite This Study

Patel et al. (1998) studied this question.

synapsesocial.com/papers/6a767e6466484ec08ac44c2ahttps://doi.org/10.1097/00000421-199806000-00025
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dose response evaluation of adriamycin in human neoplasia1977 · 388 citations
  2. 2Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.1993 · 518 citations
  3. 3Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.1995 · 527 citations
  4. 4Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.1989 · 282 citations
  5. 5Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.1989 · 239 citations